Summary of Earnings Call Company Overview - **Company**: Xylabs - **Industry**: Biotechnology, specifically focusing on oncology and immunology Key Points Company Strategy and Development - Xylabs is evolving into a globally innovative company, leveraging a profitable China business and robust R&D infrastructure [1] - The global oncology immunology pipeline is maturing, with multiple programs advancing rapidly, including JOSI, which is in a pivotal stage [2] - The company aims for its first potential US approval by 2028, with a focus on execution and preparation for 2026 [2] Financial Performance - Revenue for 2025 grew 15% year-on-year to $460 million, with Q4 revenues increasing 17% to $127.6 million [7][9] - The company reported improved operating leverage, with R&D expenses declining by 6% and SG&A expenses decreasing by 12% year-on-year [9] - A strong cash position of $790 million was maintained, positioning the company well for future investments [9] R&D Pipeline Highlights - ZOSIE, a DLL-3 targeting ADC, is a cornerstone of Xylabs' oncology portfolio, with a global Phase 3 study initiated for small cell lung cancer [3][4] - ZOSIE has shown an 80% objective response rate in patients with untreated brain metastasis, indicating its potential as a treatment option [4][12] - The company is also advancing other assets, including ZL6201 and ZL1503, targeting various cancers and autoimmune diseases [5] Market Opportunities - The total addressable market for ZOSIE in small cell lung cancer and neuroendocrine carcinomas is estimated to exceed $9 billion [4][20] - The company is focusing on expanding its presence in China, which provides access to a significant patient population and accelerates clinical trials [13] Business Development and Collaborations - Xylabs is pursuing strategic collaborations to enhance its oncology platform and explore novel combination strategies [7] - The company is divesting non-core assets to reallocate resources towards higher priority growth opportunities [7] Future Outlook - The company anticipates several meaningful pipeline catalysts in 2026, including clinical data for JOSIP and pivotal data for other programs [2] - Xylabs aims to achieve cash flow breakeven and corporate profitability, driven by growth in top-line revenue and disciplined investment in high-value global programs [16] Regulatory and Clinical Trial Insights - The company is exploring regulatory pathways for its products, including potential single-arm studies for neuroendocrine carcinomas [14][15] - Enrollment for the global trial of ZOSIE is expected to be completed by the end of Q1 2027, with a goal for accelerated approval in 2028 [17] Commercialization Strategy - The launch of CAR-XT is planned for Q2 2026, with a focus on building a commercial team and gaining physician experience with the product [23] - The company is working on increasing cycles per patient for Vivgard, aiming for a minimum of three cycles as per national guidelines [18] Additional Insights - The company is leveraging its efficient development structure in China to enhance global trial participation and speed [13] - Xylabs is committed to maintaining financial flexibility while investing in promising opportunities within oncology and immunology [24]

Financial Data and Key Metrics Changes - Total revenue grew 22% year over year to $106.5 million in Q1 2025, driven by increased sales for VivGuard, Zejula, and NUZYRA [29][30] - Operating loss improved by 20% to $56.3 million, and adjusted loss from operations decreased by 25% to $37.1 million [16][30] - The company reaffirmed its full-year revenue guidance of $560 million to $590 million, anticipating significant sales growth in the latter part of the year [8][30] Business Line Data and Key Metrics Changes - VivGuard sales are expected to grow faster than total revenue growth, with a rebound in patient volumes observed in March and April after a seasonal decline [12][36] - Other products, including Zejula and NUZYRA, delivered sequential growth supported by NRDL access, with early contributions from OGTYRO and ZACDURO [15] - The company is preparing for upcoming NRDL cycles targeting IV renewal for gMG and initial listing of the SC formulation [14] Market Data and Key Metrics Changes - The company noted a significant opportunity in the gMG market in China, with approximately 70,000 patients, and less than 10% currently receiving newer biologic therapies [63] - The competitive landscape for gMG is expected to benefit from the introduction of new therapies, which will enhance overall market education and treatment options [63] Company Strategy and Development Direction - The company aims to expand its global R&D pipeline, with a focus on differentiated and high-potential assets, including GL1310 and other novel therapies [9][10] - Investments are being made to accelerate the global R&D pipeline, with plans to present updated Phase I data at ASCO [10][20] - The company is committed to achieving profitability by Q4 2025, leveraging operational efficiencies and a robust late-stage opportunity pipeline [30][31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue targets and surpassing $2 billion by 2028, with strong momentum expected to carry into the 2030s [9] - The management team highlighted the importance of strategic initiatives to extend treatment duration and improve patient access [12][14] - The company remains optimistic about its financial position, ending Q1 with a cash position of $857.3 million [31] Other Important Information - The company is advancing its internal pipeline while also considering external opportunities for in-licensing [102][103] - Regulatory discussions with the FDA are ongoing, with no significant changes noted in the approval process despite recent leadership changes at the FDA [53][105] Q&A Session Summary Question: Can you provide more color on VIBGART's sequential change? - Management indicated that the sequential decline was influenced by seasonality and inventory dynamics, with confidence in recovery based on strong patient volumes in April [33][36] Question: Are you comfortable with consensus estimates for VIBGART and fiscal year revenues? - Management reaffirmed their revenue guidance and expressed confidence that VIBGART sales would grow faster than overall business rates [42][44] Question: How do recent FDA changes impact Zai Lab? - Management noted no anticipated impact from tariffs and indicated that FDA interactions have remained productive [50][53] Question: What is the competitive landscape for gMG in China? - Management believes that new approvals will benefit the market and enhance treatment options for patients [63] Question: What is the strategy regarding in-house developed assets? - The company plans to maintain a balanced approach between in-house development and external licensing opportunities [102][103]

Financial Data and Key Metrics Changes - Total revenue grew 22% year over year to $106.5 million in Q1 2025, driven by increased sales for VivGuard, Zejula, and NUZYRA [27] - Operating loss improved by 20% to $56.3 million, and adjusted loss from operations decreased by 25% to $37.1 million, reflecting operational efficiency [15][27] - The company reaffirmed its full-year revenue guidance of $560 million to $590 million, anticipating significant sales growth in the latter part of the year [6][28] Business Line Data and Key Metrics Changes - VivGuard sales are expected to grow faster than total revenue growth, with a rebound in patient volumes observed in March and April after a seasonal decline [11][12] - Other products, including Zejula and NUZYRA, showed sequential growth supported by NRDL access, with early contributions from newly launched products like OGTYRO and ZACDURO [14] - The company is preparing for the upcoming NRDL cycle targeting IV renewal for gMG and initial listing of the SC formulation, effective January 1, 2026 [12] Market Data and Key Metrics Changes - The company noted a significant opportunity in the gMG market in China, with approximately 70,000 patients, and less than 10% currently receiving newer biologic therapies [60] - The competitive landscape for gMG is expected to benefit from the introduction of new therapies, which will enhance overall market education and treatment options [60] Company Strategy and Development Direction - The company aims to expand its global R&D pipeline, with a focus on innovative therapies and maintaining a balanced approach between in-house development and business development opportunities [8][100] - Investments are being made to accelerate the global R&D pipeline, with a commitment to advancing at least one global product to IND submission stage every year [23] - The company is focused on achieving profitability by Q4 2025, leveraging operational efficiencies and a robust late-stage pipeline [15][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving profitability by Q4 2025, citing strong business fundamentals and strategic direction [6][27] - The company anticipates accelerating sales growth in the next three quarters, which will translate into significant operating leverage [6] - Management highlighted the importance of new product launches and regulatory approvals in driving future growth [15][28] Other Important Information - The company ended the quarter with a strong cash position of $857.3 million, providing a solid foundation for future investments and growth initiatives [29] - The company is actively pursuing regulatory reviews for multiple products, including CAR XT for schizophrenia and TIVDAC for cervical cancer [15] Q&A Session Summary Question: Can you describe the sequential change in VIBGART sales? - Management indicated that the sequential decline was influenced by seasonal trends and inventory dynamics, with a strong recovery in patient volumes observed in March and April [31][32] Question: Are you comfortable with the current consensus for VIBGART and fiscal year revenues? - Management reaffirmed confidence in the revenue guidance range of $560 million to $590 million, indicating that VIBGART sales are expected to grow faster than overall sales growth [41] Question: How do recent FDA changes and tariffs impact Zai Lab? - Management noted no anticipated impact from tariffs, as local manufacturing is in place for many products, and FDA interactions have remained productive [46][50] Question: What is the competitive landscape for gMG in China? - Management expressed optimism about the competitive dynamics, stating that new approvals will benefit the overall market and enhance treatment options for patients [60] Question: What is the strategy regarding in-house developed assets versus in-licensing? - Management indicated a balanced approach, continuing to pursue both in-house development and high-quality external opportunities [100]